Niagen Bioscience, Inc. · NASDAQ:NAGE
Niagen Bioscience — ChromaDex — Investor Presentation (January 2012)
32 slides from Niagen Bioscience's investor presentation, Jan 27, 2012
Slide 1: ChromaDex Investor Presentation January 2012
EX 99.1 C ) ChromaDex January 2012 Investor Presentation
Slide 2: Disclaimers
Disclaimers 2 Safe Harbor ‘This presentationand otherwmtten ororal statements made from timeto time by representatives of ChromaDex contain “forwart!Jooking statements" within the ‘meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21£ of the SecuritiesExchange Act of 1934
Slide 3: Disclaimers (continued)
Disclaimers (continued) Forecasts All forecasts are provided by management in this presentation and are based on information available to us at this time and management expects that internal projections and expectations may change over time. In addition, the forecasts are entirely on management's be
Slide 4: ChromaDex At a Glance
ChromaDex® At a Glance 4 « Founded 1999 e Headquarters: Irvine, CA « Analytical Laboratory: Boulder, CO » Employees: Approximately 70 Publicly-listed in 2008 4 a * Symbol (Exchange): CDXC (OTCBB) Irvine, CA Boulder, CO —— « Total Shares Outstanding- 74.9M (or 101.5M including warrants and options) »
Slide 5: ChromaDex Management Team
ChromaDex® Management Team 5 Jeffrey Himmel Bill Spengler Frank Jaksch Tom Varvaro Ann Deren-Lewis CEO President cso CFO VP Marketing © Chairman & CEO, The © Previous roles: © Founded ChromaDex in © Previously CFO of Fast. © Previously VP at Merz Himmel Group — EVP & CFO. MGI Pharma 1999 Heat © Lead
Slide 6: ChromaDex is at an Inflection Point
re ChromaDex is at an Inflection Point as it le ‘44 Launches B|G Sciencé and Commercializes its Cd Pipeline of Proprietary Products Founded Publicly-listed 1999 2008 2011 2012 BlaScience Proprietary Products Legacy Business ©
Slide 7: ChromaDex's Legacy Business is a Premier Partner with the Natural Products Industry
ChromaDex’s Legacy Business is a Premier 7 Partner with the Natural Products Industry Natural productfine chemicals Analytical & chemistry-based services _ f @ Used for QA & R&D Testing for identity, © 3000+ Plant-based fine 7 potency, safety chemicals © Manufacturing R&D © QA/ QC & regulatory consu
Slide 8: The Legacy Business is Positioned For Growth
The Legacy Business is Positioned 8 For Growth Increased consumer demand — natural products industry expected to reach $243B by 2015! Increased R&D by global blue-chip players — e.g. Pepsi Global Nutrition Group, Nestle Health Sciences Increased regulatory scrutiny — FDA implementation of GMPs and i
Slide 9: The Legacy Business Fuels a Pipeline of Proprietary Products — the pTeroPure example
2007 2008 The Legacy Business Fuels a Pipeline of Proprietary Products — the pTeroPure® example 2009 2010 | 9 2011 2008: Begins collaborating with USDA to provide reference standards for R&D 2008-2008: In-licenses use patents 2011: Launches Blu Science, from USDA and a process patent from a manufact
Slide 10: The Launch of ChromaDex's First Proprietary Product is Underway
vee The Launch of ChromaDex’s First Proprietary es j Product is Underway 10 & » # plerePure _ The first proprietary compound, sold as an ingredient 85 BI a Pa ien ce offering, featuring plersPure The fusion of blueberries and s ChromaDex’s first branded consumer ©
Slide 11: pTeroPure ChromaDex-Branded Pterostilbene
| 41 - wy isa plerePure ChromaDex-Branded Pterostilbene a « Pterostilbene is a phytoalexin (plant defense system) found naturally in blueberries « Apolyphenol with high bioavailability and a long half-life in the body as comparedto Resveratrol « Aproven compound offering safety and health benefits t
Slide 12: pTeroPure Highlights
12 pleréPure Highlights » Awarded Frost & Sullivan’s 2010 “Most Promising Health Ingredient of the Year” © Clinical trial is underway atthe University of Mississippi + Double-blind, randomized, placebo-controlled, IRB-reviewed + Endpoints: cholesterol levels, triglycerides & blood pressure; oxidativ
Slide 13: pTeroPure has potential in billion-dollar markets
pleréPure has potential in billion-dollar markets pTeroPure Dietary Supplements G3 2010 Uric Food & Beverage Q3 2011 Animal Health Qi 2012 BluScience ~ Retail line Dietary Supplements 3 2011 Cosmeceuticals 4.2012 Sun Care 2 2013 pleréPure | 13
Slide 14: pTeroPure Serves Two Large and Growing Markets
pler$Puré Serves Two Large and Growing Markets | +4 Functional Foods Nutritional Supplements and Beverages + 2010 Sales: $28.4B pler@Purc + 2010Sales: $38.38 + 2005-2010 CAGR: 7.4% + 2005-2010 CAGR: 8.0% Incorporated into productlines of 15+ early Incorporated into a line of organic foods adopters i
Slide 15: pTeroPure Revenue Provides a Growth Catalyst
pler@Pure Revenue Provides a Growth Catalyst 15 Revenue from pTeroPure sales as an ingredient to third parties expected to grow from less than $1M in 2011 to approaching target of $20M per year in 3-5 years. Key drivers: « PR efforts on pTeroPure health benefits, tied to clinical studies + BlGScienc
Slide 16: ChromaDex's Branded Supplement Line, BluScience, is Rolling out Nationally
ChromaDex's Branded Supplement Line, 16 BlGSciencé, is Rolling out Nationally Current offerings New SKU in Q1 2012 8 8° 3° = ty i 30' eo fi BluScience BlUSCieNce Bluscience Blu Science Blu Sciences *@#e *¢ EternalBid HeartBlu LrimBlu Blu2Go MemoryBla ei & tra Ea ‘eae ae ae ——=—_——__ Capsules and ora
Slide 17: BluScience is Experiencing Rapid Uptake with Mass Merchants
BlaSciencé is Experiencing Rapid Uptake with Mass Merchants |17 Walgreens 8100 Launched GNC 1700 (corporate stores) Launched drugstore es Online retailer Launched MSKESSON 5000 cvs 7000 CardinalHealth 5000 aw 4800 Walmart >'< 3600 CosTrco 420 >30,000 Total outlets Al forecasts ar provided by managem
Slide 18: Why BluScience is Creating a Buzz Among National Retailers
Why Bla Sciencé is Creating a 18 Buzz Among National Retailers Extensive Science * Potent anti-oxidant pleréPure pterostilbene * Other ingredients selected for widely-accepted health and anti-oxidant benefits, most with clinical studies of their own * Dosing at efficacious levels * Clinical trials b
Slide 19: BluScience has Aligned Key Partners to Support the Launch
BlaSciencé has Aligned Key Partners to 19 Support the Launch into Mass Market : CHANDLER CHICCO alcone i COMPANIES 2010 Agency ofthe Year Holmes Report Healthcare Agency of the Decade ‘ana DOS EQUIS H ZANTAC LISTERINE 75 ich’s
Slide 20: Detailed Marketing Plans Developed to Support the BluScience Launch
Detailed Marketing Plans Developed to Support the BIGSciencé Launch Aa fas \/ Print Ads ‘ Gor gle E © ong inline Ads \ brities o a om Ne ss ve
Slide 21: BluScience Net Sales Forecast at Key Distribution Points
Bla Sciencé Net Sales Forecast’ at Key Distribution Points 21 USD (Millions) GNC, Clubs, Wholesalers $120 - mPharmacies = Discount Dept. Stores $110 $100 - H ' As a % of Net Sales $80 - ' 2012 2013 & beyond $60 | | Gross Profit 51% 56% 05 i oA | Sales & Marketing 43% 19% $20 - | expense + Baseline s
Slide 22: pTeroPure has Significant Near-term Potential as a Cosmeceutical
pleréPure has Significant Near-term Potential as ,, a Cosmeceutical Science Overview e Research demonstrates the ability to inhibit skin damage & aging effects caused by oxidative stress e Promotes skin lightening by inhibiting melanogenesis (darkening of skin) e _ Lipophilic structure makes it pote
Slide 23: pTeroPure has Significant Opportunity in Sun Care
pleréPure has Significant Opportunity in Sun Care, Supported by a Joint Patent with UC Irvine | 23 The joint patent with UC Irvine: * Science overview: exposure to UV light activates enzymes (COX-2 and 12-LOX) that damage cellular structure while inactivating proteins (15-PDGH and UGT) that naturall
Slide 24: Initial Clinical Study on Cholesterol May Demonstrate Rx Potential
The Initial Clinical Study on Cholesterol May Demonstrate Significant Potential for pleréPure as an Rx Offering | 24 University of Mississippi study will be the 15‘in a series of clinical trials on pathway to pharmaceutical approval - One-third of hyperlipidemic patients in the trial are on statin t
Slide 25: ChromaDex will Commercialize its Other Proprietary Products
ChromaDex will Commercialize its Other Proprietary Products while Building a Pipeline of Next-generation Compounds | 25 Compound _ Applications Intellectual Property + Cholesterol + Use patents-pending from University Prerostibene * Blood pressure _of Mississippi and with UC Irvine TersP + Oxidative
Slide 26: Total Company Net Sales Forecasts
USD (Millions) $180 5 Ingredients $160 - ™Skin Care mLegacy Business $140 - mBluScience $120 - $100 - $97 $80 - $60 - $40 - $30 $20 $0 $126 “Baseline scenario. Al forecasts are provided by management inthis presentation for lusative purposes only and ae based an infomation avaiable fo us [ths tne, M
Slide 27: BluScience Net Income Forecasts
BlG Sciencé Net Income Forecasts 27 USD Millions $50 Worst case - 80% of baseline Gross Sales $42 = Baseline #20 = Best Case - 125% of Gross Sales 30 ° $27 $ $28 $30 $18 $21 $18 $20 $15 $9 $10 2011 2012 $0 + r 1 5) 2013 2014 2015 -$10 Pr ($1 a -$20 - AU forecasts are provided by management inthis pr
Slide 28: ChromaDex In Summary
ChromaDex® In Summary 28 1%'branded dietary supplementline - launched 2" half 2011 at GNC » Mass Retail Distribution and Advertising Launch in Q1 2012 BlaScience™ * Features ChromaDex’s proprietary and award winning pTeroPure® « Products and IP with potential in several billion-dollar markets: Signi
Slide 29: ChromaDex Investment Highlights
1) ChromaDex Investment Highlights 29 B!G Sciencé is an exceptional new dietary supplement brand with high uptake expected at mass merchant retailers in 2012. pleréPure , the first commercialized proprietary compound, has significant potential in billion-dollar markets and is the core ingredient in
Slide 30: Contact Information
Contact Information 30 ChromaDex, Inc. 10005 Muirlands Blvd., Suite G Irvine, CA 92618 Phone: +1-949-419-0288 Fax: +1-949-419-0294 www.chromadex.com Investor Relations Bob Prag, President Scott Wilfong, President The Del Mar Consulting Group, Inc. Alex Partners, LLC Phone: 858.794.9500 Phone: 425.24
Slide 31: Appendix
Appendix 31 ©
Slide 32: Shareholder summary
Shareholder summary Shareholder Number of Shares percenY Ownership Dr. Phillip Frost 14,319,606 19.06% Frank L. Jaksch Jr. 7,666,652 10.21% Barry Honig 6,694,597 8.91% John Liviakis 4,020,961 5.35% Michael H. Brauser 3,666,425 4.88% TOTAL 36,368,248 48.41% 32 ©